A clinical trial published in the New England Journal of Medicine suggests that long-acting injectable HIV treatment offered immediately to patients with detectable virus could work better for those who find daily oral medication difficult to manage.
The findings come from the SUPLA trial, a randomised controlled study — meaning patients were assigned to treatment groups by chance, which is considered the most reliable way to test a medical intervention. Writing in an NEJM Voices blog post, infectious disease specialist Paul Sax explained that the trial strengthens the case for offering injectable antiretroviral therapy (ART) — medication that suppresses HIV in the body — straight away to people who have detectable levels of virus in their blood and who struggle to take a pill every day.
At present, daily oral tablets are the standard approach to HIV treatment. But sticking to that schedule can be genuinely hard for some patients, and missed doses can allow the virus to replicate. Injectable ART, given less frequently, removes the daily routine entirely.
The SUPLA trial is randomised, which gives its findings more weight than observational studies. According to the NEJM post, the results support making injectable treatment available as an immediate option — not a last resort — for patients with viraemia (detectable HIV in the bloodstream) who are not managing well on oral therapy.
NHS England oversees access to HIV treatments in England, including in Kent. Anyone with questions about their HIV medication or treatment options should speak to their HIV clinic or GP in the first instance. NHS 111 can also advise on accessing the right service.
Key information
- Speak to your HIV clinic or GP if you have concerns about your current HIV treatment or want to ask about alternative options
- NHS 111 (call 111) can help you find the right local service if you are unsure where to turn
- Terrence Higgins Trust helpline: 0808 802 1221 — free support and information on HIV treatment and services across the UK
Source: @NEJM